Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31232781 | 0.99 | CRBN (0.51) | CRBNDDB1POLBGSPT1PRKCQ | |
| SCHEMBL30705998 | 0.85 | CRBN (0.48) | CRBNDDB1POLBGSPT1PRKCQ | |
| SCHEMBL31585504 | 0.80 | CRBN (0.56) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30769320 | 0.80 | CRBN (0.56) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26641368 | 0.78 | CRBN (0.54) | CRBNDDB1POLBGSPT1 | |
| Trifluoroacetic Acid SCHEMBL31232773 | 0.78 | DDB1 (0.45) | CRBNDDB1GSPT1 | |
| SCHEMBL24125814 | 0.78 | CRBN (0.64) | CRBNDDB1POLB | |
| SCHEMBL25187957 | 0.78 | CRBN (0.64) | CRBNDDB1POLB | |
| SCHEMBL30817371 | 0.77 | CRBN (0.56) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL24548169 | 0.77 | CRBN (0.60) | CRBNDDB1POLBGSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | CRBN 184/4885DDB1 291/4885POLB 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.